Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Sunil R HingoraniCraig E Devoe

Abstract

This phase Ib study evaluated the safety and tolerability of PEGylated human recombinant hyaluronidase (PEGPH20) in combination with gemcitabine (Gem), and established a phase II dose for patients with untreated stage IV metastatic pancreatic ductal adenocarcinoma (PDA). Objective response rate and treatment efficacy using biomarker and imaging measurements were also evaluated. Patients received escalating intravenous doses of PEGPH20 in combination with Gem using a standard 3+3 dose-escalation design. In cycle 1 (8 weeks), PEGPH20 was administrated twice weekly for 4 weeks, then once weekly for 3 weeks; Gem was administrated once weekly for 7 weeks, followed by 1 week off treatment. In each subsequent 4-week cycle, PEGPH20 and Gem were administered once weekly for 3 weeks, followed by 1 week off. Dexamethasone (8 mg) was given pre- and post-PEGPH20 administration. Several safety parameters were evaluated. Twenty-eight patients were enrolled and received PEGPH20 at 1.0 (n = 4), 1.6 (n = 4), or 3.0 μg/kg (n = 20), respectively. The most common PEGPH20-related adverse events were musculoskeletal and extremity pain, peripheral edema, and fatigue. The incidence of thromboembolic events was 29%. Median progression-free survival (PFS...Continue Reading

References

Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Oct 23, 1997·International Review of Cytology·S B McLeskeyP M Saling
Nov 4, 2004·The Lancet Oncology·Alok A Khorana, Robert L Fine
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Oct 28, 2010·Molecular Cancer Therapeutics·Curtis B ThompsonGregory I Frost
May 3, 2011·Magnetic Resonance Imaging·Sivaramakrishnan RajaramanNatarajan Raghunand
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Nov 22, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A MaraveyasG Bozas
Jul 12, 2012·Nature Biotechnology·Mallika Singh, Napoleone Ferrara
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Feb 20, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Clifford J WhatcottHaiyong Han
May 20, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Uwe PelzerHanno Riess

❮ Previous
Next ❯

Citations

Apr 21, 2016·Cancers·Daniel ZeitouniKirsten L Bryant
May 24, 2016·Current Opinion in Cell Biology·Jennifer Alexander, Edna Cukierman
Dec 13, 2016·Wiley Interdisciplinary Reviews. Systems Biology and Medicine·Lance L Munn
Mar 11, 2017·Journal of Oncology Practice·Kenneth P Olive
May 12, 2016·Biophysical Journal·Christopher C DuFortSunil R Hingorani
Jan 18, 2017·Cancer Letters·Janaiah KotaMurray Korc
May 26, 2017·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Charlotte CarlierWim Ceelen
Oct 1, 2016·Expert Opinion on Drug Delivery·Ayesha KhalidJoy Wolfram
Jun 24, 2017·International Journal of Molecular Sciences·Aleksandra AdamskaMarco Falasca
Nov 11, 2017·Nature Reviews. Cancer·Mark W Dewhirst, Timothy W Secomb
Dec 1, 2017·The Cancer Journal·Andrew J Aguirre, Eric A Collisson
Jun 24, 2017·World Journal of Clinical Oncology·Songchuan GuoJennifer Wu
Jan 10, 2018·Frontiers in Pharmacology·Bo ZhangZhiqing Pang
Mar 16, 2018·American Journal of Physiology. Gastrointestinal and Liver Physiology·Christopher J HalbrookCostas A Lyssiotis
Jun 22, 2018·American Journal of Physiology. Gastrointestinal and Liver Physiology·Sandeep NadellaJill P Smith
Oct 11, 2017·Gut·Ji Young BangShyam Varadarajulu
Dec 13, 2018·Expert Opinion on Investigational Drugs·Sreenivasa ChandanaDaruka Mahadevan
Mar 1, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ramesh K RamanathanHoward S Hochster
Mar 13, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea Wang-Gillam
Mar 7, 2019·The Journal of Pathology·Ralph H HrubanLaura D Wood
May 1, 2019·Cancers·Madelaine G van MackelenberghHanneke W M van Laarhoven
Jun 1, 2019·Expert Review of Anticancer Therapy·Veethika Pandey, Peter Storz
Jun 27, 2018·EMBO Molecular Medicine·Andrea ResoviRaffaella Giavazzi
Oct 21, 2019·Biomedical Chromatography : BMC·Amir ShakouriJalal Abdolalizadeh
Dec 13, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sunil R HingoraniAndrew E Hendifar
Jul 8, 2020·International Journal of Molecular Sciences·Irene RamosDolores Pérez-Sala
Sep 12, 2018·Cancers·Maximilian WenigerAndrew S Liss

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.